Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study.

Cureus 2020 Sep 11;12(9):e10380. Epub 2020 Sep 11.

Gastroenterology Unit, King Fahad Hospital, Jeddah, SAU.

Background Hepatitis B Virus (HBV) continues to be a significant global health problem despite vaccination programs and effective antiviral drugs. Aim Assess tenofovir alafenamide fumarate (TAF) as a new treatment modality in light of the clinical characteristics of HBV patients. Settings and design A real-world observational study Methods and material We collected data of 71 HBV patients and recorded the hepatitis B virus deoxyribonucleic acid (HBV-DNA) plasma levels and biochemistry test results for the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine levels at three time points, including baseline, time of switching to TAF, and six months after switching. Results From the time of switching to TAF till six months later, HBV-DNA plasma levels significantly decreased from 838.61 IU/mL to 16.7 IU/mL (p-value of <0.05). ALT and AST levels dropped from 29.05 U/L to 27 U/L and from 21.34 U/L to 20.7 U/L (p-values 0.328 and 0.410, respectively). Although TAF did not show a statistically significant reduction in the serum levels of AST, ALT, and creatinine, it showed a detectable maintenance level. Conclusions In the evaluated cohort, all clinical characteristics of HBV were maintained six months after switching patients to TAF.

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.10380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550005PMC
September 2020

Publication Analysis

Top Keywords

hepatitis virus
12
alafenamide fumarate
8
switching taf
8
hbv-dna plasma
8
time switching
8
observational study
8
hbv patients
8
tenofovir alafenamide
8
clinical characteristics
8
real-world observational
4
fumarate taf
4
design real-world
4
serum creatinine
4
study methods
4
material collected
4
baseline time
4
methods material
4
taf treatment
4
settings design
4
characteristics hbv
4

Similar Publications